Company / Net Income
Seres Therapeutics, Inc. Net Income History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$113.7M
FY2025
5-year range
-$113.7M / -$65.6M
FY2021-FY2025
Trend
-73.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$114M in FY2025 to -$6M in FY2015.
Based on SEC 10-K filings.
-$114M in FY2025.
Declined from -$89M to -$114M over the past 3 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 73.4% year-over-year.
- Peak net income was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$113.7M | -73.4% |
| FY2023 | -$65.6M | +26.4% |
| FY2022 | -$89.1M | -26.8% |
| FY2021 | -$70.3M | +29.0% |
| FY2020 | -$98.9M | -10.7% |
| FY2019 | -$89.4M | +2.4% |
| FY2018 | -$91.6M | -67.2% |
| FY2017 | -$54.8M | -227.8% |
| FY2016 | -$16.7M | -173.8% |
| FY2015 | -$6.1M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026